FHTX vs. GTHX, IMMP, ACRV, GBIO, MACK, OVID, PRLD, QURE, CDT, and GALT
Should you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include G1 Therapeutics (GTHX), Immutep (IMMP), Acrivon Therapeutics (ACRV), Generation Bio (GBIO), Merrimack Pharmaceuticals (MACK), Ovid Therapeutics (OVID), Prelude Therapeutics (PRLD), uniQure (QURE), Conduit Pharmaceuticals (CDT), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical preparations" industry.
Foghorn Therapeutics (NASDAQ:FHTX) and G1 Therapeutics (NASDAQ:GTHX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk.
Foghorn Therapeutics presently has a consensus price target of $14.50, indicating a potential upside of 178.31%. G1 Therapeutics has a consensus price target of $9.33, indicating a potential upside of 133.92%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Foghorn Therapeutics is more favorable than G1 Therapeutics.
G1 Therapeutics has higher revenue and earnings than Foghorn Therapeutics. G1 Therapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
Foghorn Therapeutics has a beta of 3.13, meaning that its share price is 213% more volatile than the S&P 500. Comparatively, G1 Therapeutics has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.
In the previous week, G1 Therapeutics had 2 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for G1 Therapeutics and 1 mentions for Foghorn Therapeutics. G1 Therapeutics' average media sentiment score of 1.48 beat Foghorn Therapeutics' score of 0.00 indicating that G1 Therapeutics is being referred to more favorably in the news media.
61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 24.2% of G1 Therapeutics shares are held by institutional investors. 9.2% of Foghorn Therapeutics shares are held by insiders. Comparatively, 8.2% of G1 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
G1 Therapeutics has a net margin of -58.13% compared to Foghorn Therapeutics' net margin of -288.17%. Foghorn Therapeutics' return on equity of 0.00% beat G1 Therapeutics' return on equity.
G1 Therapeutics received 274 more outperform votes than Foghorn Therapeutics when rated by MarketBeat users. Likewise, 65.66% of users gave G1 Therapeutics an outperform vote while only 57.69% of users gave Foghorn Therapeutics an outperform vote.
Summary
Foghorn Therapeutics and G1 Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Foghorn Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Foghorn Therapeutics Competitors List
Related Companies and Tools
